A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs ARC 520 (Primary) ; Entecavir; Tenofovir
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Arrowhead Pharmaceuticals
  • Most Recent Events

    • 02 Dec 2016 Status changed from suspended to discontinued.
    • 21 Nov 2016 Planned End Date changed from 1 Nov 2017 to 1 May 2018.
    • 21 Nov 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top